Pavinetant

Global Polycystic Ovary Syndrome (PCOS) Market Study, 2015-2026: Key Marketed & Pipeline Drugs, Clinical Trials, Patent Information, 10-Year Disease Incidence Forecast, Licensing & Acquisition Deals - ResearchAndMarkets.com

Retrieved on: 
Monday, March 30, 2020

This Market Spotlight report covers the Polycystic Ovary Syndrome market, comprising key pipeline and marketed drugs, clinical trials, patent information, and a 10-year disease prevalence forecast, as well as licensing and acquisition deals.

Key Points: 
  • This Market Spotlight report covers the Polycystic Ovary Syndrome market, comprising key pipeline and marketed drugs, clinical trials, patent information, and a 10-year disease prevalence forecast, as well as licensing and acquisition deals.
  • The approved drugs in the PCOS space target estrogen receptor 1, androgen receptor, and follicle stimulating hormone receptor.
  • Therapies in the pipeline for PCOS focus on targets such as AMP-activated protein kinase, neurokinin receptor, and gonadotropin-releasing hormone receptor.
  • Merck KGaA leads industry sponsors with the highest overall number of clinical trials for PCOS, followed by AstraZeneca and Merck & Co.

World Polycystic Ovary Syndrome (PCOS) Market Spotlight 2017-2018 & 2018-2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 19, 2019

The "Market Spotlight: Polycystic Ovary Syndrome (PCOS)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Spotlight: Polycystic Ovary Syndrome (PCOS)" report has been added to ResearchAndMarkets.com's offering.
  • This Market Spotlight report covers the Polycystic Ovary Syndrome market, comprising key pipeline and marketed drugs, clinical trials, patent information, and a 10-year disease prevalence forecast, as well as licensing and acquisition deals.
  • The approved drugs in the PCOS space target estrogen receptor 1, androgen receptor, and follicle stimulating hormone receptor.
  • Merck KGaA leads industry sponsors with the highest number of clinical trials for PCOS, followed by AstraZeneca and Merck & Co.

Global Polycystic Ovary Syndrome (PCOS) Market 2018-2028: Merck KGaA Leads Industry Sponsors with the Highest Number of Clinical Trials for PCOS, Followed by AstraZeneca and Merck & Co

Retrieved on: 
Monday, May 14, 2018

This Market Spotlight report covers the Polycystic Ovary Syndrome market, comprising key pipeline and marketed drugs, clinical trials, patent information, and a 10-year disease prevalence forecast, as well as licensing and acquisition deals.

Key Points: 
  • This Market Spotlight report covers the Polycystic Ovary Syndrome market, comprising key pipeline and marketed drugs, clinical trials, patent information, and a 10-year disease prevalence forecast, as well as licensing and acquisition deals.
  • The approved drugs in the PCOS space target estrogen receptor 1, androgen receptor, and follicle stimulating hormone receptor.
  • Merck KGaA has the highest number of completed clinical trials for PCOS, with five in total.
  • Merck KGaA leads industry sponsors with the highest number of clinical trials for PCOS, followed by AstraZeneca and Merck & Co.